The FY19 Defense Appropriation provides $125 million (M) to the Department of Defense Psychology Health/Traumatic Brain Injury Research Program (PH/TBIRP) to support critical psychological health (PH) - and traumatic brain injury (TBI)-related research and development efforts to benefit Service members, Veterans, and other beneficiaries of the military health system. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The U.S. Army Medical Research and Materiel Command (USAMRMC) Congressionally Directed Medical Research Programs (CDMRP) provides execution management support for DHA research program areas, including the Joint Program Committee-8/Clinical and Rehabilitative Medicine Research Program (JPC-8/CRMRP). The managing agent for this Program Announcement is the CDMRP with strategic oversight from the JPC-8/CRMRP.

The JPC-8/CRMRP seeks to implement long-term strategies to develop knowledge and materiel products to reconstruct, rehabilitate, and provide definitive care for injured Service members.  The ultimate goal is to return Service members to duty and improve their quality of life. The PH/TBIRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY19 PH/TBIRP Complex TBI Rehabilitation Research (CTRR) Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in July 2019. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the government.

FY19 PH/TBIRP will solicit research applications for the following CTRR Areas of Emphasis (all three bulleted areas are for CRA; only 2^nd and 3^rd areas are for CTA):

• ·       Return to Duty (RTD) Risk Assessment; Computational Model Development or Validation

• Integrate objective mild TBI (mTBI) patient data from multiple domains through computational modeling to inform RTD capability 
• Clinical support tool leveraging computational modeling to measure and communicate risk associated with returning injured warfighters to duty following mTBI

• ·       Determination of the Objective Outcome Measures of Brain Impairment after mTBI with Existing FDA cleared Devices

• Develop objective measure(s) of brain function that determine severity of functional impairment
• Correlate brain function to RTD performance

• ·       Optimization of Treatment Strategy based on Patient Classification to improve management of patients with mTBI as described above

Projects focused on other research areas relevant to the intent of the CTRR-CRA may be submitted for consideration, provided that sufficient justification is included in the application.

https://cdmrp.army.mil/pubs/press/2019/19phtbipreann_ctrr

CTRR – Clinical Research Award (CTRR-CRA)

Independent investigators at all academic levels (or equivalent)

• Supports applied and translational research to advance the development of knowledge and materiel products for rehabilitation and restoration of function following TBI.
• Supported research can include preclinical studies using human subjects or samples and observational or mechanistic clinical research studies.
• Clinical trials are not allowed.
• Preclinical research using animals is not allowed.
• Must address one or more FY19 PH/TBIRP CTRR Areas of Emphasis.
• Preproposal is required; application submission is by invitation only.

• Maximum funding of $2.0M for total costs (direct plus indirect costs).
• Maximum period of performance is 3 years.

CTRR – Clinical Trial Award (CTRR-CTA)

Independent investigators at all academic levels (or equivalent)

• Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, Phase 0), to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.
• Interventions should be limited, existing, and manualized. Studies may include seeking to optimize dosing in existing interventions.
• Preclinical studies are not allowed.
• Must address one or more FY19 PH/TBIRP CTRR Areas of Emphasis.
• Preproposal is required; application submission is by invitation only.
• Maximum funding of $4.0M for total costs (direct plus indirect costs),
• Maximum period of performance is 3 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcement and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the Program Announcement is released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PH/TBIRP, or other CDMRP-administered programs, please visit the CDMRP (https://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY19 Defense Appropriation provides $20 million (M) to the Department of Defense Joint Program Committee 8/Clinical and Rehabilitative Medicine Research Program (JPC-8/CRMRP) to support the development of regenerative medicine solutions and technical capabilities that repair, reconstruct, or regenerate tissue lost or damage due to traumatic injury through collaborative partnerships and synergistic projects that inform and build on each other.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

The JPC-8/CRMRP is offering the Regenerative Medicine Focused Research Award (RMFRA) as its next iteration of the Armed Forces Institute of Regenerative Medicine (AFIRM), AFIRM III, in FY19 to continue its effort to support the development of regenerative medicine solutions.  The FY19 JPC-8/CRMRP Program Announcement and General Application Instructions for the RMRFA mechanism are posted on the Grants.gov website. 

Focus Areas and Areas of Encouragement

All projects submitted under the FY19 JPC-8/CRMRP RMFRA will be required to address one or both of the following Focus Areas:

• Peripheral nerve regeneration
• Skeletal muscle regeneration

Efforts to regenerate peripheral nerve should focus on restoring maximal function; the goal should be accelerating functional recovery and/or reducing the need for autograft; efforts should not simply address metrics of nerve regrowth or conduits to cross nerve gaps.  Similarly efforts to regenerate skeletal muscle should extend beyond restoration of muscle bulk or structure and address restoration of maximal muscle function.  The FY19 JPC-8/CRMRP RMFRA Areas of Encouragement include:

• Immediate reconnection of severed peripheral nerves (e.g., preventing Wallerian degeneration)
• Regeneration of composite muscle and nerve injuries leading to improved function
• Regenerative therapies for volumetric muscle loss
• Preservation of denervated end organs
• Maintenance of the motor end plate or regeneration of the neuromuscular junction
• Improving the rate of peripheral nerve regeneration

https://cdmrp.army.mil/funding/jpc8

Regenerative Medicine Focused Research Award (RMFRA) – Preproposal due August 7, 2019

Independent investigators at all academic levels (or equivalent)

·      Preproposal is required; full application submission is by invitation only.

·      Accommodates either Single Principal Investigator (PI) or Multiple PI submissions.  All research teams should include highly qualified investigators. Partnerships should include multidisciplinary investigators that bring resources and expertise that combine to create a robust, synergistic collaboration.

·      Supports the development of regenerative medicine technical capabilities and solutions through collaborative partnerships and synergistic projects (Multiple PI submissions) or through comprehensive projects (Single PI submissions) to accelerate regenerative medicine solutions and technical capabilities that repair, reconstruct, or regenerate tissue lost or damaged due to traumatic injury

·      Multi-institutional collaborations between/among academia, industry, and Department of Defense and/or Department of Veterans Affairs facilities are highly encouraged.

·      Research projects should be either advanced preclinical research or early stage clinical trials (Phase 0, I, or IIa)

·      Applications must address one or both of the FY19 Joint Program Committee 8/CRMRP RMFRA Focus Areas

·     Maximum funding of $10 million (M) for total costs (direct plus indirect costs).

·     Submissions may range in size and scope as appropriate for the work proposed, and will be equally considered.  Submissions with a total of less than the maximum  of $10M are encouraged

·     Maximum period of performance is 5 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcement and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the JPC-8/CRMRP, please visit the CRMRP website (https://crmrp.amedd.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

                                                   

www.facebook.com/TheCDMRP

The FY19 Defense Appropriation provides $20 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP)to support research of exceptional scientific merit in the area of kidney cancer.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 KCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

https://cdmrp.army.mil/funding/kcrp

Academy of Kidney Cancer Investigators - Dean Award – Letter of Intent due September 17, 2019

Dean must be an established kidney cancer researcher.

·      Supports visionary individuals who are established kidney cancer researchers with a strong record of mentoring and commitment to leadership.

·      Academy Dean will oversee an interactive virtual academy of Early-Career Investigators and their designated mentors, facilitate regular interactive communication among all Academy members, and assess the research progress and career progression of the Early-Career Investigators.

·     Maximum funding of $625,000 for direct costs (plus indirect costs).

·      Maximum period of performance 5 years.

·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

Academy of Kidney Cancer Investigators - Early Career Investigator Award – Letter of Intent due September 17, 2019

Must be within 3 years of his/her last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent as of full application submission deadline.

Letter attesting to eligibility required.

·      Supports addition of new Early-Career Investigators to the unique, interactive virtual academy providing intensive mentoring, national networking, and a peer group for junior faculty.

·      Early-Career Investigators whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.

·      A Designated Mentor who is an experienced kidney cancer researcher with kidney cancer funding is required.

·      The Designated Mentor not required to be at the same institution as the Early-Career Investigator.

·      Preliminary data required.

·      Clinical trials are not allowed.

·     Maximum funding of $725,000 for direct costs (plus indirect costs).

·      Maximum period of performance 4 years.

·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

Clinical Consortia Award – Letter of Intent due September 17, 2019

Independent Investigators at or above the level of Assistant Professor (or equivalent)

·      Supports development of a consortium that will facilitate rapid execution of collaborative clinical trials that will bring to market high-impact, novel therapeutics that will ultimately and significantly decrease the impact of kidney cancer.

·      Funds may not be used for research or development of clinical protocols.

·      Trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer encouraged.

·      One Coordinating Center and three clinical trial sites will be selected and be jointly responsible for proposing, selecting, and conducting trials.

·      Sites must provide plans for accruing patients from populations disproportionately affected by kidney cancer

·      Consortium expected to achieve financial self-sufficiency, such that operations can continue after the award ends.

·      The consortium is expected to achieve financial self-sufficiency, such that operations can continue after the award period ends.

Coordinating Center:

·      Maximum funding of $3M for direct costs (plus indirect costs).

·     Maximum period of performance is 3 years.

·     Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

Clinical Trial Sites:

·     Maximum funding of $600,000 for direct costs (plus indirect costs).

·      Maximum period of performance is 3 years.

·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

The FY19 Defense Appropriation provides $10 million (M) to the Department of Defense Orthotics and Prosthetics Outcomes Research Program (OPORP) to support research that evaluates the comparative effectiveness of orthotic and prosthetic clinical interventions using patient-centric outcomes for Service members and Veterans who have undergone limb amputation.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 OPORP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

OPORP awards are focused on outcomes-based best practices through analysis of the merits of prosthetic and orthotic device options currently available, not on the development of new or the improvement of existing technology.  The intent of the awards is to generate clinically useful evidence that will enhance and optimize patient outcomes.

Focus Areas:  The OPORP will only consider applications that specifically address the critical needs of the orthotics and prosthetics outcomes research community in one or more of the FY19 Focus Areas.  The OPORP will solicit research applications that address at least one of the following FY19 Focus Areas:

• Orthotic or Prosthetic Device Form:  Understand patient outcomes through the analysis and characterization of variables related to the form of currently available clinical options such as device size, shape, material, and/or configurations.
• Orthotic or Prosthetic Device Fit:  Understand patient outcomes related to human-device interface and component connection through the analysis of variables in currently available clinical options that facilitate fit-related metrics such as comfort and/or usability.
• Orthotic or Prosthetic Device Function:  Understand patient outcomes through the analysis of variables related to currently available device function such as device control, sensors, and passive or active response with respect to activities of daily living and other real-world activities.

https://cdmrp.army.mil/funding/oporp

Clinical Research Award – Letter of Intent due July 24 2019

Independent investigators at all academic levels (or equivalent)

• Supports research that evaluates orthotic and/or prosthetic devices using patient-centric outcomes relevant to Service members and Veterans with limb loss and/or limb impairment
• Proposed projects should be designed to provide outcomes data regarding orthotic and/or prosthetic devices and must include the anticipated effect on patient care metrics.
• Multidisciplinary collaboration among academia, industry, the DoD, the Department of Veterans Affairs (VA), and other Federal Government agencies is highly encouraged.
• Applications submitted to the FY19 OPORP CRA must address one or more of the FY19 OPORP Focus Areas.
• Animal studies are not allowed.
• Clinical trials are not allowed.
• The FY19 CRA offers two funding levels:

Funding Level 1:

·      Maximum funding of $350,000 for total costs (direct costs plus indirect costs)

·      Maximum period of performance is 2 years

Funding Level 2:

·      Maximum funding of $1,000,000 for total costs (direct costs plus indirect costs)

·      Maximum period of performance is 4 years

Clinical Trial Award – Letter of Intent due July 24, 2019

Independent investigators at all academic levels (or equivalent)

• Supports rapid implementation of clinical trials with the potential to make significant impacts on improving the health and well-being of Service members, Veterans, and other individuals living with limb deficit.
• Supports clinical trials that evaluate orthotic and/or prosthetic devices using patient-centric outcomes.
• Proposed projects should be designed to provide outcomes data regarding orthotic and/or prosthetic devices and must include the anticipated effect on patient care metrics.
• Multidisciplinary collaboration among academia, industry, the military Services, the VA, and other Federal Government agencies is highly encouraged.
• Applications submitted to the FY19 OPORP CTA must address one or more of the FY19 OPORP Focus Areas.
• Preclinical research is not allowed.

The FY19 CTA offers two funding levels:

Funding Level 1:

·      Maximum funding of $350,000 for total costs (direct costs plus indirect costs)

·      Maximum period of performance is 2 years

Funding Level 2:

·      Maximum funding of $2,000,000 for total costs (direct costs plus indirect costs)

·      Maximum period of performance is 4 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the OPORP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

The FY19 Defense Appropriation provides $20 million (M) to the Department of Defense Joint Program Committee 8/Clinical and Rehabilitative Medicine Research Program (JPC-8/CRMRP) to support the development of regenerative medicine solutions and technical capabilities that repair, reconstruct, or regenerate tissue lost or damage due to traumatic injury through collaborative partnerships and synergistic projects that inform and build on each other.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

The JPC-8/CRMRP is offering the Regenerative Medicine Focused Research Award (RMFRA) as its next iteration of the Armed Forces Institute of Regenerative Medicine (AFIRM), AFIRM III, in FY19 to continue its effort to support the development of regenerative medicine solutions.  The JPC-8/CRMRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications for the RMFRA.  The FY19 JPC-8/CRMRP Program Announcement and General Application Instructions for the RMRFA mechanism are anticipated to be posted on the Grants.gov website in June 2019.  Pre-application and application deadlines will be available when the Program Announcement is released.  This pre-announcement should not be construed as an obligation by the government.

Focus Areas and Areas of Encouragement

All projects submitted under the FY19 JPC-8/CRMRP RMFRA will be required to address one or both of the following Focus Areas:

• Peripheral nerve regeneration
• Skeletal muscle regeneration

Efforts to regenerate peripheral nerve should focus on restoring maximal function; the goal should be accelerating functional recovery and/or reducing the need for autograft; efforts should not simply address metrics of nerve regrowth or conduits to cross nerve gaps.  Similarly efforts to regenerate skeletal muscle should extend beyond restoration of muscle bulk or structure and address restoration of maximal muscle function.  The FY19 JPC-8/CRMRP RMFRA Areas of Encouragement include:

• Immediate reconnection of severed peripheral nerves (e.g., preventing Wallerian degeneration)
• Regeneration of composite muscle and nerve injuries leading to improved function
• Regenerative therapies for volumetric muscle loss
• Preservation of denervated end organs
• Maintenance of the motor end plate or regeneration of the neuromuscular junction
• Improving the rate of peripheral nerve regeneration

https://cdmrp.army.mil/pubs/press/2019/19dmrdppreann_jpc8

Regenerative Medicine Focused Research Award (RMFRA)

Independent investigators at all academic levels (or equivalent)

·      Preproposal is required; full application submission is by invitation only.

·      Accommodates either Single Principal Investigator (PI) or Multiple PI submissions.  All research teams should include highly qualified investigators. Partnerships should include multidisciplinary investigators that bring resources and expertise that combine to create a robust, synergistic collaboration.

·      Supports the development of regenerative medicine technical capabilities and solutions through collaborative partnerships and synergistic projects (Multiple PI submissions) or through comprehensive projects (Single PI submissions) to accelerate regenerative medicine solutions and technical capabilities that repair, reconstruct, or regenerate tissue lost or damaged due to traumatic injury

·      Multi-institutional collaborations between/among academia, industry, and Department of Defense and/or Department of Veterans Affairs facilities are highly encouraged.

·      Research projects should be either advanced preclinical research or early stage clinical trials (Phase 0, I, or IIa)

·      Applications must address one or both of the FY19 JPC-8/CRMRP RMFRA Focus Areas

·     Maximum funding of $10,000,000 for total costs (direct plus indirect costs)

·     Submissions may range in size and scope as appropriate for the work proposed, and will be equally considered.  Submissions with a total of less than the maximum  of $10M are encouraged

·     Maximum period of performance is 5 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcement and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the Program Announcement is released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the JPC-8/CRMRP, please visit the CRMRP website (https://crmrp.amedd.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY19 Defense Appropriation provides $20 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP)to support research of exceptional scientific merit in the area of kidney cancer.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 KCRP Program Announcements and General Application Instructions for the following award mechanisms are e posted on the Grants.gov website.

https://cdmrp.army.mil/funding/kcrp

Concept Award – Letter of Intent due September 17, 2019

All investigators at or above the level of postdoctoral fellow (or equivalent) are eligible.

• Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer
• Emphasis on innovation
• Clinical trials not allowed
• Preliminary data not allowed
• Blinded review
• Maximum funding of $75,000 for direct costs (plus indirect costs)
• Maximum period of performance 1 year
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement

Idea Development Award – Letter of Intent due September 17, 2019

Established Investigators: 

Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree; or

Early Career Investigators:

Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline are eligible

·      Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer

·      Preliminary data required

·      Innovation and Impact are the most important review criteria

·      Clinical trials not allowed

• FY19 KCRP Areas of Emphasis strongly encouraged
• Maximum funding of $400,000 in direct costs (plus indirect costs)
• Maximum period of performance 2 years
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement

Translational Research Partnership Award – Letter of Intent due September 17, 2019

The Initiating PI must be at or above the level of Assistant Professor or equivalent.

The Partnering PI must be at or above the level of Assistant Professor or equivalent.

Postdoctoral fellows are not eligible to be Partnering PIs.

·      Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications

·     Supports translational correlative studies

·      Preliminary data required

·      Clinical trials not allowed

·     Maximum funding of $600,000 for direct costs (plus indirect costs)

·      Maximum period of performance 3 years

·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507
help@eBrap.org

The FY19 Defense Appropriation provides $12 million (M) to the Department of Defense Reconstructive Transplant Research Program (RTRP) to support research projects that specifically address needs in the field of vascularized composite allotransplantation (VCA).  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 RTRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

Focus Areas:  To meet the intent of the FY19 RTRP Idea Discovery Award and Investigator-Initiated Research Award mechanisms, applicants must address at least one of the FY19 RTRP Focus Areas listed below:

• ·        Reduce the risks of VCA-associated immunosuppression
• o   Define the unique mechanisms of VCA immunogenicity
• o   Develop novel approaches for improving VCA immune tolerance
• o   Identify unique immunosuppression requirements for VCA compared to other solid organ transplants
• ·        Develop reliable non-invasive methods or tools for monitoring VCA graft rejection
• o   Develop reliable non-invasive biomarkers for monitoring chronic VCA graft rejection in a large animal model
• o   Identify and/or validate new peripheral biomarkers for acute and chronic rejection
• o   Develop assays or devices for clinical graft monitoring utilizing validated biomarkers
• ·        Advance existing or develop innovative ex vivo tissue preservation strategies to extend the timeline between procurement and transplantation
• o   Develop novel approaches and models for perfused, hypothermic, high subzero and low subzero, or static preservation strategies
• o   Determine the extent to which VCA tissue preservation technology impacts VCA immunogenicity

https://cdmrp.army.mil/funding/rtrp

Idea Discovery Award – Preapplication due July 17, 2019

Investigators at or above the level of postdoctoral fellow (or equivalent)

• Supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods.
• Innovation is the most important review criterion.
• Project should include a well-formulated testable hypothesis based on strong scientific rationale and study design.
• Preliminary or published data that supports the rationale are strongly encouraged.
• Preproposal is required; full application submission is by invitation only.
• Applications must address at least one of the FY19 RTRP Focus Areas.
• • Reduce the risks of VCA-associated immunosuppression
  • Develop reliable non-invasive methods or tools for monitoring VCA graft rejection
  • Advance existing or develop innovative ex vivo tissue preservation strategies to extend the timeline between procurement and transplantation

·      Maximum funding of $500,000 for total costs (direct plus indirect costs).

• ·      Maximum period of performance is 2 years.

Investigator-Initiated Research Award – Preproposal due July 17, 2019

Independent investigators at all academic levels (or equivalent)

• Supports studies with the potential to make an important contribution to the reconstructive transplant research field, patient care, and/or quality of life.
• Preproposal is required; full application submission is by invitation only.
• Preliminary or published data are required.
• Multiple PI Option supports synergistic partnerships among two to four investigators collaborating on a single application; multi-institutional collaborations are encouraged.
• Applications must address at least one of the FY19 RTRP Focus Areas.
• • Reduce the risks of VCA-associated immunosuppression
  • Develop reliable non-invasive methods or tools for monitoring VCA graft rejection
  • Advance existing or develop innovative ex vivo tissue preservation strategies to extend te timeline between procurement and transplantation

Individual PIs:

·      Maximum funding of $1 million (M) for total costs (direct plus indirect costs).

·      Maximum period of performance is 3 years.

Multiple PI Option:

·      Maximum funding of $1.5M for total costs (direct plus indirect costs).

• ·      Maximum period of performance is 3 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural Funding Opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the RTRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.rog

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) Research and Development Directorate J9 manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

The FY19 AIMM Program Announcement and General Application Instructions for the following award mechanism are posted on Grants.gov. 

Applications submitted to the FY19 AIMM initiative must address at least one of the following Focus Areas:

• Algorithms/tools for decision support in a deployed or operational environment to: diagnose military-relevant disease, illness, or injury; prescribe mitigation and treatment strategies; and/or determine risk of Warfighter return to duty.    
• Artificial Intelligence (AI)/deep learning for integrating heterogeneous data streams and analyzing data from wearables to support making informed healthcare decisions.  Wearable sensor systems may pertain to, but are not limited to, the following or combinations of the following:  infectious disease diagnosis; physiologic status monitoring; informing real-time casualty location and triage; and/or environmental monitoring.     
• AI/deep learning for analyzing and interrogating large medical data sets to: identify patterns/predictors of disease, illness, or injury; and/or identify treatment outcomes.

https://cdmrp.army.mil/funding/dmrdp

AIMM Research Award – Preproposal due July 26, 2019

Independent investigators at all academic levels (or equivalent)

• Supports highly creative and conceptually innovative high-risk research with the potential to accelerate critical discoveries or major advancements that will significantly impact military health and medicine; not intended to support incremental advances on previous or ongoing work.
• Supports applied research efforts that initiate or enhance potential game-changers that may not be supported by other funding mechanisms or core programs.
• Applications must address at least one of the FY19 Focus Areas, which include algorithms/tools for decision support in a deployed or operational environment, and AI/deep learning for integrating heterogeneous data streams and analyzing data from wearables to support making informed healthcare decisions, as well as for analyzing and interrogating large medical data sets
• Cross-cutting, broadly applicable projects with the potential to benefit multiple DoD medical research program areas are highly encouraged.
• Presentation of preliminary data is not required, though not prohibited.
• Maximum funding of $350,000 for direct costs (plus indirect costs)
• Maximum period of performance is 18 months

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcement and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all USAMRMC funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcement is released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507
help@eBrap.org

The FY19 Defense Appropriation provides $20 million (M) to the Department of Defense Vision Research Program (VRP)to support impactful military-relevant vision research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 VRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

Applications submitted to the FY19 VRP must address at least one of the following Focus Areas:

• Eye injury or visual dysfunction as related to a military-relevant traumatic event.  Examples of military-relevant trauma may include, but are not limited to:

○       Blast, blunt, thermal, or chemical trauma

○       Trauma caused by directed energy weapons such as laser, microwaves, and particle beams

• Diagnosis and treatment of eye injuries in austere environments and prolonged field care settings

https://cdmrp.army.mil/funding/vrp

Focused Translational Team Science Award (FTTSA) – Preproposal due August 6, 2019

·        The overall Principal Investigator (PI) must be an independent investigator at or above the level of Associate Professor (or equivalent) with demonstrated success in leading large collaborative research project(s).

·        Leaders of individual projects may be independent investigators at all academic levels (or equivalent).

·        The overall lead PI is required to devote a minimum of 20% effort to this award.

Preproposal is required; application submission is by invitation only.

• Supports a highly collaborative and translational team initiative that will fundamentally advance the understanding and treatment of eye injury and/or visual dysfunction that result from a military-relevant trauma.

• Must address one or more of the FY19 VRP Focus Areas.

• Applications shall include at least three but no more than five distinct research projects that together form a concerted and synergistic effort to address an overarching challenge.

• Preliminary data required for each individual project.

• One of the projects may include a pilot clinical trial where limited clinical testing of a novel intervention is conducted to inform the feasibility, rationale, and design of subsequent clinical trials.

• Must have a detailed Implementation Plan for participating research groups to coordinate efforts, facilitate collaboration, and create synergy.

• Maximum funding of $5,000,000 for direct costs (plus indirect costs)
• The maximum period of performance is 4 years.

Investigator-Initiated Research Award (IIRA) – Preproposal due August 6, 2019

Independent investigators at all academic levels (or equivalent).

Preproposal is required; application submission is by invitation only.

·      Supports studies that will yield highly impactful discoveries or major advancements in research and/or patient care of eye injury and/or visual dysfunction as related to military-relevant trauma.

·      Must address one or more of the FY19 VRP Focus Areas.

·      Funding Level 1 supports exploratory, high-risk/high-reward research in the earliest stages of development. No preliminary data is required.

·      Funding Level 2 supports the advancement of more mature research toward clinical translation.  Preliminary data required. 

·      It is the responsibility of the applicant to select the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the stage and maturity of the research, rather than the amount of the budget.

·      Clinical trials are not allowed

Funding Level 1:

·        Maximum funding of $260,000 for direct costs (plus indirect costs)

·        The maximum period of performance is 2 years.

Funding Level 2:

·        Maximum funding of $500,000 for direct costs (plus indirect costs)

·        The maximum period of performance is 3 years.

Translational Research Award (TRA) – Preproposal due August 6, 2019

Independent investigators at all academic levels (or equivalent).

Preproposal is required; application submission is by invitation only.

·      Supports translational research that moves promising laboratory research into clinical applications.

·      It is expected that an Investigational New Drug (IND)/Investigational Device Exemption (IDE) application will be submitted during or by the end of the period of performance.

·      Must address one or more of the FY19 VRP Focus Areas.

·      Preliminary data required.

·        May include a pilot clinical trial component where limited clinical limited clinical testing of a novel intervention is conducted to inform the feasibility, rationale, and design of subsequent clinical trials.

·        Maximum funding of $750,000 for direct costs (plus indirect costs)

·        The maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.  

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://ebrap.org/.  For more information about the VRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

The FY19 Defense Appropriation provides $3.2 million (M) to the Department of Defense Duchenne Muscular Dystrophy Research Program (DMDRP) to support innovative, high-impact Duchenne muscular dystrophy research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 DMDRP Program Announcement and General Application Instructions for the following award mechanism is posted on the Grants.gov.

IMPORTANT:  All applications for the FY19 DMDRP Idea Development Award must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that address primary pathology of DMD. Eligible therapeutic strategies include: gene therapy, genome editing, oligonucleotide therapies, exon skipping, protein therapeutics, and cell therapies.

Studies proposed under this award may include:

·        Delivery to skeletal muscle and heart (ligand assisted, nanoparticles, identification of biological barriers to delivery, alternative vectors)

·        Immunosuppression, and other strategies to deal with neutralizing antibodies

·        Re-dosing

·        Targeting muscle stem cells

·        Cell based therapies, including but not limited to: selection of novel cell types, expansion, root of delivery, differentiation, and integration

Studies proposed under this award should not include:

• Therapies addressing secondary pathology of DMD (fibrosis, inflammation, muscle atrophy, oxidative stress, mitochondrial defects, abnormal peripheral circulation)
• Small molecules
• Efficacy testing absence of mechanistic understanding,
• Evaluation of standard vectors or delivery technologies

https://cdmrp.army.mil/funding/dmdrp

Idea Development Award

Principal Independent investigator (PI): Independent investigators at all academic levels (or equivalent) are eligible to be names as a PI.

• Supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accerale progress in improving outcomes for individuals with DMDM.
• Applications must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that address primary pathology or DMD.
• Preliminary data are required.
• Clinical trials are not allowed.
• Maximum funding of $350,000 in direct costs (plus indirect costs)
• Period of performance not to exceed 2 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the DMDRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org